Skip to main content
SpringerLink
Log in

Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures

  • Letter
  • Published:
Osteoporosis International Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Popp AW, Zysset PK, Lippuner K (2016) Rebound-associated vertebral fractures after discontinuation of denosumab—from clinic and biomechanics. Osteoporos Int 27:1917–1921

    Article  CAS  PubMed  Google Scholar 

  2. Lamy O, Gonzalez-Rodriguez E, Stoll D, Hans D, Aubry-Rozier B (2016) Severe rebound-associated vertebral fractures after denosumab discontinuation: nine clinical cases report. J Clin Endocrinol Metab jc20163170

  3. Shepherd JA, Schousboe JT, Broy SB, Engelke K, Leslie WD (2015) Executive summary of the 2015 ISCD position development conference on advanced measures from DXA and QCT: fracture prediction beyond BMD. J Clin Densitom 18:274–286

    Article  PubMed  Google Scholar 

  4. Bauer DC (2011) Discontinuation of odanacatib and other osteoporosis treatments: here today and gone tomorrow? J Bone Miner Res 26:239–241

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rheumatological Practice OsteoRheuma Bern, 3011, Bern, Switzerland

    T. Lehmann

  2. Department of Rheumatology, Immunology and Allergology, University Hospital and University of Bern, CH-3012, Bern, Switzerland

    D. Aeberli

Authors
  1. T. Lehmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Aeberli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Aeberli.

Ethics declarations

Any grants or fellowships supporting the writing of the paper

None.

Disclosures

None.

Conflict of interest

Thomas Lehmann and Daniel Aeberli declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lehmann, T., Aeberli, D. Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures. Osteoporos Int 28, 3067–3068 (2017). https://doi.org/10.1007/s00198-017-4108-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-017-4108-y

Search

Navigation